Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Study in biliary tract cancer finds the solution achieved 83.5% overall concordance rate with expert interpretations.
The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.
Read More
A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.
Read More
Johns Hopkins researchers found the blood test detected multiorgan tissue damage in patients experiencing immune-related adverse events from checkpoint inhibitor therapy.
Read More
A study of 431 patients demonstrates the test can detect cancer recurrence months ahead of standard imaging.
Read More
Research analyzing cell-free DNA fragmentation patterns in healthy individuals reveals physiological confounders that could improve test accuracy.
Read More
Transaction expands Natera’s solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.
Read More
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read More
The new guidelines allow self-collected vaginal samples for HPV testing and outline criteria for safely discontinuing cervical cancer screening.
Read More
The test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.
Read More
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
Read More
The standards developed through a public-private partnership contain seven oncogenic mutations selected for clinical significance.
Read More
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Read More
Research demonstrates the MRD assay’s utility in tracking disease progression and predicting treatment outcomes.
Read More
The blood-based screening test can detect more than 200 types of solid tumor cancers and is now available in all 48 continental states.
Read More
The agreement extends CNSide cerebrospinal fluid test coverage to 16 million additional patients nationwide.
Read More